PDAC cells express sodium–glucose transporters (including SGLT2), and preclinical work shows functional SGLT-mediated glucose uptake that can be blocked by SGLT2 inhibitors, with growth suppression in pancreatic cancer models; however, clinical evidence for a direct anticancer effect is limited [45]. Here, SLC5A2 is linked to pancreatic neoplasm.